Literature DB >> 26659704

Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Jernej Dolinšek1, Petra Rižnik2, Larisa Sabath2, Dušanka Mičetić-Turk2.   

Abstract

OBJECTIVES: Inflammatory bowel disease (IBD) in children has a remitting and relapsing course. The aim of our study was to evaluate the value of fecal calprotectin (FC), C-reactive protein (CRP), and clinical scores in predicting endoscopic and histological lesions in children with IBD.
METHODS: A total of 68 children with IBD (29 with ulcerative colitis (UC), 39 with Crohn's disease (CD), mean age 14.2 years) were included in the study. We retrospectively reviewed clinical scores (PUCAI, PCDAI), CRP values, endoscopic, and histological data as well as FC values in all included children.
RESULTS: In children with UC, the correlation between the histological lesions and FC (r = 0.609, p < 0.01), CRP (r = 0.390, n.s.), or PUCAI (r = 0.535, p < 0.05) was higher than for children with CD (FC r =  0.490, n.s.; CRP r =  0.269, n.s.; PCDAI r = 0.257, n.s.). The correlation between endoscopy scores and the same parameters yielded similar findings (UC: FC r = 0.628, p < 0.01; CRP r = 0.387, n.s.; PUCAI r = 0.256, n.s.; CD: FC r = 0.516, p < 0.05; CRP r = 0.238, n.s.; PCDAI r = 0.267, n.s.). The correlation between FC and PUCAI (r = 0.532, p < 0.01) was higher than that between CRP and PUCAI (r = 0.424, p < 0.01). However, the correlation between FC and PCDAI (0.384, p < 0.01) is lower than that between CRP and PCDAI (r = 0.447, p < 0.01).
CONCLUSION: FC is a better predictor of the severity of endoscopic and histological lesions than CRP or disease activity scores, especially for UC. FC, as a noninvasive marker, could possibly be used to reduce the number of endoscopic procedures in children with a confirmed diagnosis of IBD.

Entities:  

Keywords:  Calprotectin; Children; Diagnosis; Endoscopy; Inflammatory bowel disease

Mesh:

Substances:

Year:  2015        PMID: 26659704     DOI: 10.1007/s00508-015-0915-3

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  30 in total

1.  Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.

Authors:  S K Bunn; W M Bisset; M J Main; B E Golden
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-02       Impact factor: 2.839

2.  Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.

Authors:  E Olafsdottir; L Aksnes; G Fluge; A Berstad
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

3.  The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.

Authors:  İbrahim Koral Önal; Yavuz Beyazit; Burçin Şener; Burak Savuk; Diğdem Özer Etık; Abdurrahim Sayilir; Erkin Öztaş; Serkan Torun; Yasemin Özderın Özın; Bilge Tunç Demırel; Aysel Ülker; Ülkü Dağli
Journal:  Turk J Gastroenterol       Date:  2012       Impact factor: 1.852

4.  Faecal calprotectin in children with chronic gastrointestinal symptoms.

Authors:  Alan Bremner; Sohere Roked; Rebecca Robinson; Ian Phillips; Mark Beattie
Journal:  Acta Paediatr       Date:  2005-12       Impact factor: 2.299

5.  Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.

Authors:  Michael A Quail; Richard K Russell; Johan E Van Limbergen; Pam Rogers; Hazel E Drummond; David C Wilson; Peter M Gillett
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

6.  Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.

Authors:  A Diamanti; F Colistro; M S Basso; B Papadatou; P Francalanci; F Bracci; M Muraca; D Knafelz; P De Angelis; M Castro
Journal:  Inflamm Bowel Dis       Date:  2008-09       Impact factor: 5.325

7.  Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease.

Authors:  Marzena Komraus; Halina Wos; Sabina Wiecek; Maciej Kajor; Urszula Grzybowska-Chlebowczyk
Journal:  Mediators Inflamm       Date:  2012-05-14       Impact factor: 4.711

8.  Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis.

Authors:  Kaija-Leena Kolho; Dan Turner
Journal:  ISRN Gastroenterol       Date:  2013-02-26

Review 9.  The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Paul Henderson; Niall H Anderson; David C Wilson
Journal:  Am J Gastroenterol       Date:  2013-05-14       Impact factor: 12.045

10.  ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.

Authors:  Arie Levine; Sibylle Koletzko; Dan Turner; Johanna C Escher; Salvatore Cucchiara; Lissy de Ridder; Kaija-Leena Kolho; Gabor Veres; Richard K Russell; Anders Paerregaard; Stephan Buderus; Mary-Louise C Greer; Jorge A Dias; Gigi Veereman-Wauters; Paolo Lionetti; Malgorzata Sladek; Javier Martin de Carpi; Annamaria Staiano; Frank M Ruemmele; David C Wilson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-06       Impact factor: 3.288

View more
  1 in total

1.  Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?

Authors:  Aleksandra Czajkowska; Katarzyna Guzinska-Ustymowicz; Anna Pryczynicz; Dariusz Lebensztejn; Urszula Daniluk
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.